174422-22-1

Upstream product

• 329-59-9 4-fluoro-3-nitro-benzoic acid methyl ester 
• 104-86-9 4-chlorobenzylamine 
• 453-71-4 3-nitro-4-fluorobenzoic acid 
• 14719-83-6 methyl 3-nitro-4-chlorobenzoate 
• 96-99-1 4-chloro-3-nitrobenzoate 

Downstream Products

• 174422-23-2 methyl 3-amino-4-(p-chlorobenzylamino)benzoate 
• 1168139-12-5 methyl 1-[(4-chlorophenyl)methyl]-2-methyl-1H-benzimidazole-5-carboxylate 
• 1096969-16-2 1-[(4-chlorophenyl)methyl]-2-methyl-1H-benzimidazole-5-carboxylic acid 
• 1168138-16-6 1-[(4-chlorophenyl)methyl]-2-methyl-N-[(1R)-1-phenylpropyl]-1H-benzimidazole-5-carboxamide 
• 1168139-13-6 methyl 1-(4-chlorobenzyl)-1H-benzo[d]imidazole-5-carboxylate 
• 1438983-62-0 (S)-1-(4-chlorobenzyl)-N-(1-(3-isopropylphenyl)ethyl)-1H-benzo[d]imidazole-5-carboxamide 
• 1036539-29-3 1-(4-chlorobenzyl)-1H-benzo[d]imidazole-5-carboxylic acid 
• 174422-21-0 1-(4-Chloro-benzyl)-2-(2,4-dichloro-phenyl)-1H-benzoimidazole-5-carboxylic acid 
• 174422-20-9 1-(4-Chloro-benzyl)-2-(4-chloro-phenyl)-1H-benzoimidazole-5-carboxylic acid 
• 214903-74-9 1-(4-Chloro-benzyl)-2-(4-methyl-piperazin-1-yl)-1H-benzoimidazole-5-carboxylic acid methyl ester 
• 214903-76-1 1-(4-Chloro-benzyl)-2-(4-methyl-piperazin-1-yl)-1H-benzoimidazole-5-carboxylic acid 
• 214903-71-6 2-Chloro-1-(4-chloro-benzyl)-1H-benzoimidazole-5-carboxylic acid methyl ester 
• 214903-70-5 1-(4-Chloro-benzyl)-2-oxo-2,3-dihydro-1H-benzoimidazole-5-carboxylic acid methyl ester 
• 174422-24-3 3-Amino-4-(p-chlorophenylmethyl)aminobenzoic acid 

Relevant academic research and scientific papers

3D-Printed Polypropylene Continuous-Flow Column Reactors: Exploration of Reactor Utility in SNAr Reactions and the Synthesis of Bicyclic and Tetracyclic Heterocycles

3D printing has the potential to transform the way in which chemical reactions are carried out due to its low-cost, ease-of-use as a technology and its capacity to expedite the development of iteratively enhanced prototypes. In this present study, we developed a novel, low-cost polypropylene (PP) column reactor that was incorporated into an existing continuous-flow reactor for the synthesis of heterocycles. The utility and solvent resistance of the printed devices were explored in SNAr reactions to produce substituted aniline derivatives and in the synthesis of bicyclic and tetracyclic heterocycles. Using this approach, a range of heterocyclic compounds was synthesised including the core structure of the natural product (±)-γ-lycorane and structurally complex compounds based on the tetracyclic core of the erythrina alkaloids.

Heterocyclic derivative and pharmaceutical composition comprising the same

The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect. A pharmaceutical composition having a P2X3 and/or P2X2/3 receptor antagonistic effect comprising a compoun

NOVEL HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect. A pharmaceutical composition having a P2X3 and/or P2X2/3 receptor antagonistic effect comprising a compoun

N-BENZYLBENZIMIDAZOLE MODULATORS OF PPARG

The invention provides molecular entities that bind with high affinity to PPARG (PPAR?), inhibit cdk5-mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.

Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPARγ partial agonist

The peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-activated nuclear receptor, thought to play a role in energy metabolism, glucose homeostasis and microglia-mediated neuroinflammation. A novel benzimidazole series of centrally penetrant PPARγ partial agonists has been identified. The optimization of PPARγ activity and in vivo pharmacokinetics leading to the identification of GSK1997132B a potent, metabolically stable and centrally penetrant PPARγ partial agonist, is described.

NOVEL COMPOUNDS

The invention relates to novel benzimidazole compounds of formula (I) wherein R1 to R1 are as defined in the specification, pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds that are agonists of peroxisome proliferators-activated receptorγ (PPARγ).

Synthesis and antioxidant capacities of some new benzimidazole derivatives

In this study, we prepared some new oxadiazolyl benzimidazole derivatives and investigated their antioxidant properties by determination of microsomal NADPH-dependent inhibition of lipid peroxidation levels (LP assay) and microsomal ethoxyresorufin O-deet

Synthesis and potent antimicrobial activity of some novel methyl or ethyl 1H-benzimidazole-5-carboxylates derivatives carrying amide or amidine groups

A series of benzimidazole-5-carboxylic acid alkyl ester derivatives carrying amide or amidine substituted methyl or phenyl groups at the position C-2 were synthesised and evaluated for antibacterial and antifungal activities against S. aureus, methicillin

Synthesis of some novel tetrahydronaphthalene benzimidazole derivatives

Retinoids, synthetic and natural analogues of all-trans-retinoic acid (RA), exert their biological effects with responsive elements of DNA to promote on cell differentiation and proliferation and behave as potent adipogenic hormones. Herein, we describe the synthesis of a number of novel tetrahydrotetramethylnaphthalene benzimidazole derivatives as retinoids. Analogs were prepared as depicted in Scheme 1 and 2. As is evident from both shemes, a variety of tetrahydrotetramethylnaphthalene benzimidazole derivatives have been synthesized by using an appropiate NaHSO3 addiction product.

SYNTHESIS OF 1,2-DISUBSTITUTED BENZIMIDAZOLE-5(6)-CARBOXAMIDES AND EVALUATION OF THEIR ANTIMICROBIAL ACTIVITY

A series of 14,N'-(N,N-dialkylaminoethyl)-benzimidazole-5(6) or 5-carboxamides (1-14), having several substituents on the azole and benzene nuclei, were prepared and evalueted in vitro for antimicrobial activity.The precursor bezimidazolecarboxylic acids (15-27) were prepared via oxidative condensation of diaminobenzoic acids and several aldehydes with cupric ion.Compounds 11-14 were prepared by selective regioisomer synthesis.All carboxamides were prepared from the corresponding acids and N,N-dialkylethylenediamine.Antibacterial and antifungal activities were determined as MICs values.Of the synthesized compounds 1-10, 6 and 10 were found to be most favourable.In order to clarify the effect of the substituents at N1 on antimicrobial activity, 12 was prepared by p-chlorobenzyl substitution of compound 6, and increased activity was shown.Compounds 13 and 14, which were prepared by replacement with more bulky alkyl groups on the tert-N atom than 12, gave the best results.